tirzepatide and keto on Shows Superior Weight Loss Over Semaglutide in Phase 3 Trial Quick Reference Tirzepatide ODT | Empower Pharmacy

Also, if you have multiple endocrine neoplasia syndrome type 2, a rare genetic condition that can cause thyroid cancer, your doctor will not prescribe Zepbound

Jardine MJ, Hata J, Woodward M, et al

The GLP-1 receptor agonist market in India, valued at $82.2 million in 2024, is projected for rapid growth, potentially reaching $352.3 million by 2030, with estimates suggesting the market could expand fivefold by 2030

Obesity, primarily associated with the increased burden of non-communicable diseases (NCDs), has been linked to healthcare costs approximately 30% higher than those of individuals with normal body weight [9]

Most are mild to moderate, but some patients may need to discontinue treatment